EXHIBIT 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
Tenax Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type |
| Security Class Title |
| Fee Calculation Rule |
| Amount Registered(1)(2) |
|
| Proposed Maximum Offering Price Per Share(3) |
|
| Maximum Aggregate Offering Price(3) |
|
| Fee Rate |
|
| Amount of Registration Fee |
| |||||
Equity |
| Common Stock, $0.0001 par value per share |
| Rules 457(c) and 457(h)(1) |
|
| 400,000 |
|
| $ | 4.01 |
|
| $ | 1,604,000 |
|
| $ | 0.0001476 |
|
| $ | 237 |
|
Total Offering Amounts |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ | 237 |
| ||||
Total Fee Offsets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ | 0 |
| ||||
Net Fee Due |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ | 237 |
| ||||||
| (1) | Consists of 400,000 additional shares reserved for issuance under the Tenax Therapeutics, Inc. 2022 Stock Incentive Plan, as amended (the “2022 Plan”). An aggregate of 1,100,000 shares issuable under the 2022 Plan had been previously registered pursuant to Registration Statement No. 333-266833. | ||||||||||||||
| (2) | Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers any additional shares of Registrant’s common stock that become issuable under the 2022 Plan by reason of any stock dividend, stock split, recapitalization, or other similar transaction that results in an increase in the number of outstanding shares of the Registrant’s common stock. | ||||||||||||||
| (3) | Estimated in accordance with Rules 457(c) and 457(h)(1) of the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low prices of the Registrant’s common stock on the NASDAQ Capital Market on August 27, 2024. | ||||||||||||||
